BALAXI — Balaxi Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual income statement for Balaxi Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,313	2,794	3,364	2,413	2,926
Cost of Revenue
Gross Profit	592	838	1,337	1,126	1,269
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,892	2,297	2,816	2,349	2,572
Operating Profit	421	497	548	64.1	353
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	443	545	569	20.2	287
Provision for Income Taxes
Net Income After Taxes	381	477	460	-23.9	251
Net Income Before Extraordinary Items
Net Income	381	477	460	-23.9	251
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	381	477	460	-23.9	251
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7.63	9.53	9.08	4.38	4.54
Dividends per Share